John Chapman

John Chapman is a Research Professor at Sorbonne University's Faculty of Medicine Pitié-Salpetriere and Director Emeritus at INSERM. His career bridges basic science and clinical research, focusing on cardiovascular disease mechanisms and lipid metabolism. He holds leadership roles in the French and European Atherosclerosis Societies, co-developed influential clinical guidelines, and pioneers genetic analysis in cardiovascular risk assessment. His work emphasizes lipid-lowering therapies, familial hypercholesterolemia, and lifestyle interventions.

Education: BA in Aberdeen, followed by research fellowships at Middlesex Hospital (London) and NIH-funded work at UC San Francisco. Collaborated with INSERM to establish a dedicated research unit. Leadership includes presidencies of major atherosclerosis societies and co-creation of lipid disorder management guidelines with the European Society of Cardiology.

Research Interests:

• Lipoprotein biology and atherogenesis
• Genetic determinants of cardiovascular risk
• Pharmacological innovation in lipid-lowering therapies
• Gender-specific cardiovascular risk factors

Grants/Advising: Leveraged NIH and Wellcome Trust fellowships, advised on large-scale clinical trials like the 4S Study. Mentorship initiatives include founding educational platforms PCSK9 Forum and Triglyceride Forum.

Current Work: Focuses on genetic cohort analyses (e.g., UK BioBank), novel drug targets for lipoprotein(a) and remnant particles, and addressing underrepresented areas like post-menopausal cardiovascular health.